首页> 外文会议>Conference on Drug Design and Discovery Technologies >IN SILICO AND IN VITRO STUDIES OF BENZOHYDRAZIDE ANALOGUES AS POTENT ANDROGEN RECEPTOR ANTAGONIST
【24h】

IN SILICO AND IN VITRO STUDIES OF BENZOHYDRAZIDE ANALOGUES AS POTENT ANDROGEN RECEPTOR ANTAGONIST

机译:在苯肼类似物的硅和体外研究中作为有效的雄激素受体拮抗剂

获取原文

摘要

In the late 1950s,the Prostate Cancer(PCa)is commonly diagnosed in men.The growth of PCa is largely due to the stimulation of the AR by androgens.Currently,hormonal therapy,surgery,and oral chemotherapeutic drugs are the main therapeutic for the treatments of prostate cancer.About 1,74,650 men were diagnosed and 31,620 deaths due to PCa in the U.S reported by the American Cancer Society.1 Androgens,testosterone,and Dihydrotestosterone binds with the ligand binding domain(LBD)of the androgen receptor(AR)and incite the growth of prostate cancer.There are few available drugs for androgen receptor antagonists such as bicalutamide,flutamide,and enzalutamide are used to prevent the activation of the androgen receptor.Currently,Sipuleucel-T is used as a drug for the immunotherapy to inhibit PCa.To reduce toxicity,lower the doses,and minimize drug resistance,numerous studies are enduring for the development of target based drugs.2 Recently,benzohydrazide derivative was reported for antifungal-antibacterial,anti-inflammatory,cruzipain inhibitor.Entamoeba histolytic,antimalarial,anti-tuberculosis activities,and as EGFR Tyrosine Kinase Inhibitors.Thus,benzohydrazides are the important moieties which play a vital role in effective inhibition against different cancer cell line HepG2,HeLa,A549,and MCF-7.
机译:在20世纪50年代后期,前列腺癌(PCA)通常被诊断为男性。PCA的生长主要是由于Androgens的刺激。刺激,荷尔蒙治疗,手术和口腔化学治疗药物是主要治疗药物前列腺癌的治疗。美国癌症协会报告的美国PCA诊断出1,74,650名男性,31,620人死亡.1雄激素,睾酮和二氢睾酮与雄激素受体的配体结合结构酮(AR)结合(AR )并煽动前列腺癌的生长。对于雄激素受体拮抗剂,如雄激素酰胺,氟胺和苯甲丁酰胺用于防止雄激素受体的活化剂,用于防止雄激素,Sipuleucel-T被用作免疫疗法的药物为了抑制PCA。为了减少毒性,降低剂量,并使耐药性最小化,众多研究持续用于靶向基于靶基的药物.2最近,据报道了抗真菌的苯并酰肼衍生物抗菌,抗炎,Cruzipain抑制剂.entamoeba组织溶解,抗疟,抗结核活动,以及EGFR酪氨酸激酶抑制剂。苯并肼是在有效抑制对不同癌症细胞系Hepg2,Hep2,Hela中发挥重要作用的重要部分, A549和MCF-7。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号